The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of induction therapy with gemcitabine and nab-paclitaxel followed by consolidation with mFOLFIRINOX in patients with metastatic pancreatic cancer.
Ramesh K. Ramanathan
Consultant or Advisory Role - Celgene
Honoraria - Celgene; Lilly
Research Funding - Celgene
Peter Lee
No relevant relationships to disclose
John E. Seng
No relevant relationships to disclose
Stephen Patrick Anthony
No relevant relationships to disclose
Peter J. Rosen
No relevant relationships to disclose
Raul R. Mena
No relevant relationships to disclose
Vincent J. Picozzi
Stock Ownership - Amgen
Research Funding - Clovis; FibroGen; Immunomedics; Theranostics Health
Jasgit C. Sachdev
Research Funding - Celgene
Tim Larson
No relevant relationships to disclose
Ronald Korn
Employment or Leadership Position - Imaging Endpoints
Gayle S. Jameson
No relevant relationships to disclose
Amy C. Stoll
No relevant relationships to disclose
Daniel D. Von Hoff
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
Joseph W. Leach
No relevant relationships to disclose